neurotrophic signaling raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
=== The beginning of antibody imaging === Owing to their high affinity and specificity, antibodies have been considered as suitable vehicles for imaging and therapeutics, since the beginning of the 20th Century. The first radiolabelled antibodies were used in the early 1950s and got used for cancer therapy, but it took roughly two more decades before it was demonstrated that they target human tumour associated antigens in cancer patients. Due to the hybridoma technology in 1975, monoclonal (murine) antibodies could easily be produced in practical amounts, consequently the number of studies increased drastically. However, these types of antibodies turned out to be quite troublesome, due to the triggering of the human anti-murine antibody response. Consequently chimeric, humanised and human monoclonal antibodies have been created, produced and get used nowadays. Owing to the high molecular weight of antibodies and the Fc domain of the antibody, a slow clearance from the blood and non-target tissue occurs, which results in low tumour-to-blood and tumour-to-muscle ratios. Because of this, antibodies which are going to be used for imaging purposes need to be labelled with radionuclides that have a long half-life, which increases the radiation dose to the patient. This consequently encouraged the development of lower molecular weight antibodies and resulted in the development of minibodies, diabodies, single chain variable fragments (scFv) and single domain fragments (Fv).
=== Third representation === Given uncontrolled flow rate or varied solvent composition, another representation was designed such that a different heating source and control system would allow for partial vaporization. Two different heating methods were combined because one is capable of more rapid response time while the other is slower. This combination allows the third representation of vaporizer to handle fluctuations in flow rate coming of the LC column.
Alexander McLeish. For services to Charity. Martin Gerard McTague. Low Pay Commissioner and National Chair, UK Federation of Small Businesses. For services to Small Businesses. Thomas Anthony Meadows. Lead Operations Manager, Security Services Group, Defence Infrastructure Organisation. For services to Defence. Dr. Teame Mebrahtu. For services to Education, to Refugees and to the community in Bristol. Dr. Nicholas John Merriman. Chief Executive, The Horniman Museum and Gardens. For services to the Arts and to Heritage. Gillian Jayne Millane. Co-Founder, Love Grace. For services to Charitable Fundraising and Tackling Violence Against Women. Dr. Jane Patricia Monckton-Smith. Professor of Public Protection, University of Gloucestershire. For services to Criminal Justice. Keith Morgan. Coach, Crystal Palace Weightlifting Club. For services to Sport. Andrew David Murphy. Lately Chief Operating Officer, John Lewis Partnership. For services to the British Retail Industry. Professor James Michael Olu N'Dow, DL. Professor of Urological Surgery, University of Aberdeen. For services to Cancer and Urology, and to Voluntary Work. Professor Kimberley Anne-Isola Nekaris. Head, Nocturnal Primate Research Group, Oxford Brookes University. For services to Conservation. Kenneth Paul Newton. Governing Governor, HM Prison Birmingham. For Public Service. Robert Stewart Nicol. Lately Chief Executive, Inverness Chambers of Commerce. For services to the Economy of the Highlands of Scotland. Beryce Amy Nixon. Chief Executive Officer, Exceed Learning Partnership Trust. For services to Education.
=== Biomaterials and Tissue Engineering === This program develops carriers for drug delivery and tissue regeneration scaffolds. Research combines polymer chemistry, stem cell differentiation, and 3D bioprinting to create vascular grafts, bone/cartilage replacements, and neural matrices. Studies explore relationships between material properties and biological responses.
=== Pharmacokinetics === Posaconazole is absorbed within three to five hours. It is predominantly eliminated through the liver, and has a half-life of about 35 hours. Oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state.
Sources: en.wikipedia.org
A sea ice brine pocket is an area of fluid sea water with a high salt concentration trapped in sea ice as it freezes. Due to the nature of their formation, brine pockets are most commonly found in areas below −2 °C (28 °F), where it is sufficiently cold for seawater to freeze and form sea ice. Though the high salinity and low light conditions of brine pockets create a challenging environment for marine mammals, brine pockets serve as a habitat for various microbes. Sampling and studying these pockets requires specialized equipment to accommodate the hypersaline conditions and subzero temperatures.
=== United Kingdom === GDK's first store in the United Kingdom, was opened on 6 July 2015, on Bull Street in Birmingham, England. In May 2019, it was estimated that the chain served £1 million worth of kebabs in its restaurants in the UK every week. GDK also announced their plan to open a new restaurant every two weeks for the remainder of 2019 as part of a "relentless UK growth" plan. In September 2019, GDK's Fulham Broadway site was classed as London's number one place to eat on Tripadvisor. In October 2020, it had 47 restaurants, with hopes by the company to open a further 12 by the end of 2020. In December 2020, its Peterborough new restaurant marked its 50th UK restaurant. In February 2021, the chain announced its plan to open 47 restaurants by the end of 2021 in the UK. It opened 39 new restaurants in the UK in 2021, adding to their pre-existing 52 restaurants at the start of 2021. In February 2022, the company announced its plan to open 78 more restaurants in the UK in 2022, bringing their total to 170 restaurants in the UK. Adding 2,900 workers to their 3,500 workforce at the time in the UK. The chain opened their 100th UK restaurant at their Covent Garden, London site on 10 May 2022. In June 2022, Atul Pathak, former owner of the largest McDonald's franchise in the UK of 43 restaurants, announced a partnership with GDK, with 30 planned sites to be set up in the UK as part of the deal. In January 2025, German Doner Kebab (GDK) opened its first London train station location at Victoria Station, marking its 144th UK outlet and 55th in the capital.
John Kenneth Stille subsequently reported the coupling of a variety of alkyl tin reagents in 1978 with numerous aryl and acyl halides under mild reaction conditions with much better yields (76%–99%). Stille continued his work in the 1980s on the synthesis of a multitude of ketones using this broad and mild process and elucidated a mechanism for this transformation.
32S + n → 32P + p Neutron irradiation is performed in a nuclear reactor. The other main method used to synthesize radioisotopes is proton bombardment. The proton are accelerated to high energy either in a cyclotron or a linear accelerator.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.